P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
Authors:
Open Access
- 23 June 2022
- journal article
- abstracts
- Published by Wiley in HemaSphere
- Vol. 6 (Suppl) , 1161-1162